Imaging Biomarkers - Future or Reality
Imaging has been at the heart of Medicine for many decades. However, its influence is changing as the need increases not only for diagnosis of disease, but also for quantification of disease extent, identification of suitable candidates for treatment and for testing of both treatment response or assessment of potential side effects for new treatments.
Discovery of Potent and Selective Inhibitors of Monopolar Spindle 1 (MPS1) Kinase
This talk presents the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo[3,2-c]pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition.
Genome-Scale Protein Expression Analysis of Individual Solid Tumors
Present diagnostic procedures and therapeutic strategies solid tumours rely on the detection and targeting of specific marker molecules to classify the tumour and to design an efficient therapy.
Fragment-based Approach to Multi-target Compounds
The presented work deals with the development of a fragment based strategy for dual-target drug discovery.
New Metabolomics Biomarker for Heart Failure
Metabolomics has been successfully applied to identify and validate biomarkers for congestive heart failure. Diagnosis and risk stratification of heart failure (HF) is challenging.
Choosing & Using Fragments in the Generation of Selective Kinase Inhibitors
There is often a debate about just how useful fragments are for well-established conventional targets such as protein kinases. Fragment screening however can be extremely valuable, providing critical ideas that lead to novelty, demonstrating how to achieve selectivity, helping dissect and make the most of HTS and literature compounds, alongside maximising ligand efficiency.
Creating a Clinical Diagnostic Test from Discovery Through Launch with Mass Spectrometry
Targeted mass spectrometry, called MRM or SRM, allows for the rapid quantification of hundreds of proteins in a single assay. This tool is very specific, highly quantitative and requires very little sample (e.g. < 5 uL plasma).
LC-High Resolution-MS in Clinical Labs: A Step Forward for TDM and Metabotyping
Research/routine and quantitative/qualitative analyses using LC-HR-MS will be presented for drug and peptide determinations in patients’ plasma.
Contributions of Mass Spectrometry in the Diagnosis and Management of Hypothalamic–pituitary–adrenal Axis Disorders
Mass spectrometry is increasingly used in clinical laboratories for the measurement of steroid hormones. In fact, clinical biochemistry and endocrine societies emphasize in their documents the enhanced analytical specificity for mass spectrometry measurements of steroids in comparison with conventional immunoassays.
History and Development of High Resolution Mass Spectrometry for Infectious Disease Diagnostics
This presentation will trace the continuing development of mass spectral techniques from a research tool to a frontline diagnostic platform for clinical microbiology.